MARKET

ALIM

ALIM

Alimera Sciences
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.52
+0.75
+11.08%
Closed 16:00 12/06 EST
OPEN
6.77
PREV CLOSE
6.77
HIGH
7.68
LOW
6.77
VOLUME
83.14K
TURNOVER
--
52 WEEK HIGH
18.15
52 WEEK LOW
0.0045
MARKET CAP
559.90M
P/E (TTM)
-3.0757
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ALIM and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ALIM News

  • Alimera Sciences to Participate in the LD Micro 12th Annual Main Event on December 10, 2019
  • GlobeNewswire.3d ago
  • Alimera Announces Regulatory Approval for ILUVIEN® in Benelux Countries for The Treatment of Non-Infectious Posterior Uveitis
  • GlobeNewswire.4d ago
  • Alimera Sciences to Participate in the 31st Annual Piper Jaffray Healthcare Conference
  • GlobeNewswire.11/26 13:30
  • Edited Transcript of ALIM earnings conference call or presentation 30-Oct-19 1:00pm GMT
  • Thomson Reuters StreetEvents.11/20 05:18

More

Industry

Pharmaceuticals
+0.45%
Pharmaceuticals & Medical Research
+0.49%

Hot Stocks

Name
Price
%Change

About ALIM

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through U.S. and International segment. The Company focuses on diseases affecting the back of the eye or retina. The Company's product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, Canada, Lebanon and the United Arab Emirates, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.
More

Webull offers Alimera Sciences Inc (ALIM) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.